WELLESLEY, Mass.--(BUSINESS WIRE)--Point Therapeutics, Inc. (NASDAQ: POTP) announced today that, as anticipated, Point received an additional notice of non-compliance from the staff of the Listing Qualifications Department of The NASDAQ Stock Market LLC. The notice was based upon Point’s failure to solicit proxies and hold an annual meeting of stockholders prior to December 31, 2007, as required by NASDAQ Marketplace Rules 4350(g) and 4350(e), respectively. The notice was issued in accordance with NASDAQ rules and procedures and notwithstanding the recent decision of the NASDAQ Listing Qualifications Panel (the “Panel”) which granted Point’s request for continued listing on NASDAQ, pending completion of its proposed merger with DARA BioSciences, Inc. (“DARA”) on or before January 30, 2008.
